Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Number of holders
-
9
-
Total 13F principal, excl. options
-
105,678,000
-
Principal change
-
-300,000
-
Total reported value, excl. options
-
$116,622,644
-
Value change
-
-$335,591
-
Number of sells
-
-1
-
Price
-
$1.10
Significant Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q3 2024
9 filings reported holding 03753UAB2 - APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q3 2024.
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 has 9 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $105,678,000 of principal
.
Largest 9 bondholders include DeepCurrents Investment Group LLC ($38,528,000 of principal), Linden Advisors LP ($21,767,000 of principal), LAZARD ASSET MANAGEMENT LLC ($14,704,000 of principal), Verition Fund Management LLC ($12,138,000 of principal), TENOR CAPITAL MANAGEMENT Co., L.P. ($11,950,000 of principal), D. E. Shaw & Co., Inc. ($5,000,000 of principal), WELLINGTON MANAGEMENT GROUP LLP ($1,285,000 of principal), KORNITZER CAPITAL MANAGEMENT INC /KS ($300,000 of principal), and CITIGROUP INC ($6,000 of principal).
This table shows the top 9 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.